查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球生物模拟市场：按产品、按应用、按适应症、按最终用户、按地区 - 预测（至 2029 年）
市场调查报告书
商品编码
1593545

全球生物模拟市场：按产品、按应用、按适应症、按最终用户、按地区 - 预测（至 2029 年）

Biosimulation Market by Offering, Application, Indication, End User, & Region -Global Forecast to 2029
出版日期: | 出版商: MarketsandMarkets | 英文 378 Pages | 订单完成后即时交付

价格

全球生物模拟市场规模预计将从2024年的42.4亿美元增加至2029年的91.8亿美元，2024年至2029年的复合年增长率为16.7%。

减少药物开发过程中的成本和时间的需求日益增长，是采用生物模拟工具的关键驱动因素之一。这些工具可以预测药物如何在人体中发挥作用，并有可能最大限度地减少大规模临床试验的需求。但市场也存在多重限制因素。生物模拟技术的成本非常高，对于小型公司和学术界来说是望而却步的。

调查范围
调查年份 2022-2029
基准年 2023年
预测期 2024-2029
单元 百万/十亿美元
部分 产品、应用、治疗领域、收益模式、部署模式、最终用户
目标区域 北美、欧洲、亚太地区、拉丁美洲、中东非洲

“按应用划分，药物发现在 2023 年占据生物模拟市场最大的市场占有率。”

药物发现领域在2023年占据最大的市场占有率，因为它在加速和丰富药物研究的早期阶段发挥关键作用。生物模拟创建的工具使研究人员能够在分子水平上模拟药物行为，预测与生物标的的相互作用，甚至在进入昂贵的临床前和临床试验阶段之前评估潜力，这使得识别特定的候选药物成为可能。这减少了药物开发过程中产生的时间和成本。

“按照部署模型，云端基础模式部分预计将在预测期内实现最快的增长。”

云端基础的平台具有高度的灵活性和扩充性，并且在需要执行复杂的生物模拟时可以利用大量的运算资源。这种灵活性使得云端模型非常具有成本效益，特别是对于缺乏高效能运算基础设施的小型生物技术公司和学术机构。

“预计亚太地区在预测期内的复合年增长率最高。”

该地区的成长得益于该地区製药和生物技术行业的强劲增长，特别是在中国、印度和韩国，这些国家在药物发现和开发方面进行了大量投资。该地区的市场越来越多地采用生物模拟等复杂技术来简化研发流程、降低成本并更快地将新药推向市场。

本报告研究和分析了全球生物模拟市场，提供了关键驱动因素和限制因素、竞争格局和未来趋势等资讯。

目录

第一章简介

第二章调查方法

第三章执行摘要

第 4 章重要考察

  • 生物模拟市场概况
  • 亚太地区生物模拟市场：依收益模式、依国家划分（2023 年）
  • 生物模拟市场：地理成长机会
  • 生物模拟市场：区域组成（2024-2029）
  • 生物模拟市场：已开发国家与新兴国家

第五章市场概况

  • 介绍
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会
    • 任务
  • 生态系分析
    • 软体供应商
    • 製药和生物技术公司
    • 委外研发机构（CRO）
    • 监管机构
    • 学术/研究机构
  • 案例研究分析
  • 价值链分析
  • 波特五力分析
  • 监管分析
    • 监管环境
    • 监管机构、政府机构和其他组织
  • 专利分析
    • 与生物模拟相关的专利出版物的趋势
    • 管辖区及主要申请人分析
  • 技术分析
    • 主要技术
    • 互补技术
    • 邻近技术
  • 产业趋势
    • 生物标记发现
    • 个性化医疗招聘
  • 价格分析
    • 主要企业参考价格分析：依产品（2023年）
    • 平均销售价格趋势：按地区（定性）
  • 重大会议和活动（2024-2025）
  • 主要相关利益者和采购标准
  • 影响客户业务的趋势和颠覆
  • 最终用户分析
    • 未满足的需求
    • 最终用户的期望
  • 投资金筹措场景
  • 人工智慧/生成人工智慧对生物模拟市场的影响
    • 主要用例
    • 人工智慧/产生人工智慧对互连的相邻生态系统的影响
    • 使用者准备和影响评估

第六章生物模拟市场：透过提供

  • 介绍
  • 软体
  • 服务

第七章生物模拟市场：依应用分类

  • 介绍
  • 药物发现
  • 药物开发
  • 疾病建模
  • 製造/供应链管理
  • 其他用途

第八章生物模拟市场：依治疗领域

  • 介绍
  • 瘤
  • 心血管疾病
  • 神经系统疾病
  • 感染疾病
  • 其他治疗领域

第九章生物模拟市场：依收益模式分类

  • 介绍
  • 基于许可的模型
  • 基于订阅的模式
  • 基于服务的模式
  • 计量收费模式

第10章生物模拟市场：依部署模型

  • 介绍
  • 本地部署模式
  • 云端基础模式
  • 混合模式

第十一章生物模拟市场：依最终用户分类

  • 介绍
  • 製药和生物技术公司
  • 委外研发机构
  • 学术/研究机构
  • 监管机构
  • 其他最终用户

第十二章生物模拟市场：按地区

  • 介绍
  • 北美洲
    • 北美宏观经济展望
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲宏观经济展望
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 亚太宏观经济展望
    • 中国
    • 印度
    • 日本
    • 其他亚太地区
  • 拉丁美洲
    • 拉丁美洲宏观经济展望
    • 巴西
    • 墨西哥
    • 其他拉丁美洲
  • 中东/非洲
    • 中东和非洲宏观经济前景
    • 海湾合作委员会国家
    • 其他中东/非洲

第十三章竞争格局

  • 介绍
  • 主要企业策略/主要企业
  • 收益分析（2019-2023）
  • 市场占有率分析（2023）
    • 美国塞塔拉
    • 达梭系统（法国）
    • 薛丁格公司（美国）
    • 模拟增强版（美国）
    • 先进化学发展有限公司（加拿大）
  • 主要市场公司排名
  • 企业评价矩阵：主要企业（2023年）
  • 公司评估矩阵：Start-Ups/中小企业（2023）
  • 公司评价及财务指标
  • 品牌/产品比较
  • 竞争场景

第十四章 公司简介

  • 主要企业
    • CERTARA, USA
    • DASSAULT SYSTEMES
    • SCHRODINGER, INC.
    • SIMULATIONS PLUS
    • ADVANCED CHEMISTRY DEVELOPMENT, INC.
    • CHEMICAL COMPUTING GROUP ULC
    • ROSA & CO. LLC
    • GENEDATA AG (A DANAHER COMPANY)
    • PHYSIOMICS PLC
    • IN SILICO BIOSCIENCES
    • ALLUCENT
    • OPENEYE, CADENCE MOLECULAR SCIENCES
    • CELLWORKS GROUP, INC.
    • VERISIM LIFE
    • NETABOLICS
    • CHARNWOOD DISCOVERY
    • THE MATHWORKS, INC.
    • ANSYS, INC.
  • Start-Ups/小型企业
    • INSTEM GROUP OF COMPANIES
    • INSILICO MEDICINE
    • SCM-SOFTWARE CHEMISTRY & MATERIALS
    • BIOSYMETRICS, INC.
    • ATOMWISE INC.
    • INSITRO
    • CLINITHINK

第十五章附录

Product Code: HIT 3629

The biosimulation market is projected to reach USD 9.18 billion by 2029 from USD 4.24 billion in 2024, at a CAGR of 16.7% from 2024 to 2029. Increasing need for cost and time reduction in the drug development process has been one of the major drivers in the adoption of biosimulation tools. These tools predict how the drugs will behave inside the human body, potentially minimizing the requirements of extensive clinical trials. But there are some restraining factors in the market; the cost of biosimulation technologies is discouragingly high and thus, prohibitive to small companies and the academic community.

Scope of the Report
Years Considered for the Study2022-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredMillion/Billion (USD) include
SegmentsBy Offerings, Applications, Therapeutic Area, Revenue Model, Deployment Model, and End-user
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and Middle East Africa.

"Drug Discovery held the largest market share in the biosimulation market in 2023, by application."

The biosimulation market is segmented based on application into drug discovery, drug development, disease modelling, manufacturing & supply chain management and other applications. The drug discovery segment held the largest market share in 2023, since it plays a vital role in accelerating and enriching early stages of pharmaceutical research. The tool created by biosimulation makes it possible for the researchers to simulate drug behavior at the molecular level, predict biological target interaction, even identify potential drug candidates before they reach the costly phases of preclinical and clinical trial stages. It reduces both the time and the cost incurred during the process of drug development.

"By deployment model, the cloud-based model segment is expected to register the fastest growth over the forecast period."

By deployment model, the biosimulation market is divided into on-premises, cloud-based and hybrid model. The cloud-based segment is projected to be the fastest-growing segment over the forecast period. Cloud-based platforms are much more flexible and scalable and make very significant computational resources available at the point when they are needed to run complex biosimulations. This flexibility makes cloud models highly cost-effective, particularly for smaller biotech firms and academic institutions that would lack the infrastructure for high-performance computing.

"Asia Pacific is estimated to register the highest CAGR over the forecast period."

The biosimulation market is geographically segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The Asia Pacific biosimulation market is projected to register highest CAGR during the forecast period. The growth of this region is due to an aggressive build-out of the pharmaceutical and biotechnology industry in this region, especially in China, India, and South Korea, where large investments are committed to drug discovery and development. Markets in this region increasingly embrace sophisticated technology, such as biosimulation, to rationalize their R&D processes, reduce costs, and accelerate their time-to-market for new drugs.

Breakdown of supply-side primary interviews by company type, designation, and region:

  • By Company Type: Tier 1 (40%), Tier 2 (35%), and Tier 3 (25%)
  • By Designation: Managers (40%), Directors (35%), and Others (25%)
  • By Region: North America (40%), Europe (30%), Asia Pacific (20%), Latin America (5%) and Middle East Africa (5%)

List of Companies Profiled in the Report:

    • Certara USA. (US)
    • Simulations Plus. (US)
    • Dassault Systemes (France)
    • Schrodinger, Inc. (US)
    • Advanced Chemistry Development, Inc. (Canada)
    • Chemical Computing Group ULC. (Canada)
    • Rosa & Co. LLC. (US)
    • Genedata AG (US)
    • Physiomics Plc (United Kingdom)
    • In Silico Biosciences. (US)
    • Allucent. (US)
    • OpenEye, Cadence Molecular Sciences. (US)
    • Cellworks Group, Inc. (US)
    • VeriSIM Life. (US)
    • Netabolics SRL (Italy)
    • Charnwood Discovery (United Kingdom)
    • The MathWorks, Inc. (US)
    • ANSYS, Inc (US)
    • Instem Group of Companies (United Kingdom)
    • Insilico Medicine (US)
    • SCM - Software Chemistry & Materials (Netherlands)
    • BioSymetrics, Inc. (Canada)
    • Atomwise Inc. (US)
    • insitro. US)
    • Clinithink. (US)

Research Coverage:

This research report categorizes the biosimulation market by offerings (software and services), application (drug discovery, drug development, disease modelling, manufacturing & supply chain and other applications), therapeutic area (oncology, cardiovascular disease, neurological disorders, infectious disease, and others), revenue model (license-based model, subscription-based model, service-based model, and pay-per-use model), deployment model (on-premises model, cloud-based model, and hybrid model) end user (pharmaceutical & biotechnology companies, contract research organizations (CROs), academic & research institutions, regulatory bodies and others), and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the biosimulation market. A thorough analysis of the key industry players has been done to provide insights into their business overview, offerings, and key strategies such as acquisitions, collaborations, partnerships, mergers, product/service launches & enhancements, and approvals in the biosimulation market. Competitive analysis of upcoming startups in the biosimulation market ecosystem is covered in this report.

Reasons to Buy the Report

The report will help market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall biosimulation market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

  • Analysis of key drivers: (increase in R&D investments in the pharmaceutical and biotechnology industries), restraints (lack of standardization), opportunities (use of biosimulation solution for pediatric drug development), and challenges (difficulty in matching the complexity of biological systems and processes) influencing the growth of the biosimulation market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the biosimulation market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the biosimulation market across varied regions.
  • Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the biosimulation market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players such as Certara USA. (US), Simulations Plus. (US), Dassault Systemes (France), Schrodinger, Inc. (US), Advanced Chemistry Development, Inc. (Canada), Chemical Computing Group ULC. (Canada), Rosa & Co. LLC. (US), Genedata AG (US), etc. among others in biosimulation market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKETS COVERED & REGIONAL SCOPE
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Key data from primary sources
      • 2.1.2.2 Insights from primary experts
  • 2.2 MARKET SIZE ESTIMATION
  • 2.3 DATA TRIANGULATION
  • 2.4 MARKET SHARE ESTIMATION
  • 2.5 RESEARCH ASSUMPTIONS
  • 2.6 LIMITATIONS
    • 2.6.1 METHODOLOGY-RELATED LIMITATIONS
    • 2.6.2 SCOPE-RELATED LIMITATIONS
  • 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 BIOSIMULATION MARKET OVERVIEW
  • 4.2 ASIA PACIFIC: BIOSIMULATION MARKET, BY REVENUE MODEL AND COUNTRY (2023)
  • 4.3 BIOSIMULATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • 4.4 BIOSIMULATION MARKET: REGIONAL MIX (2024-2029)
  • 4.5 BIOSIMULATION MARKET: DEVELOPED VS. EMERGING ECONOMIES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing R&D investments in pharmaceutical and biotechnology industries
      • 5.2.1.2 Growing adoption of biosimulation software by regulatory bodies
      • 5.2.1.3 Integration of technologically advanced Quantitative Systems Pharmacology (QSP)
      • 5.2.1.4 Need to curtail drug discovery and development costs
      • 5.2.1.5 Growth in biologics and biosimilars markets
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Lack of standardization
      • 5.2.2.2 Data availability and quality
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Emerging applications
      • 5.2.3.2 Use of biosimulation solutions for pediatric drug development
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Difficulties in matching complexity of biological systems and processes
      • 5.2.4.2 Shortage of biosimulation and modeling experts
  • 5.3 ECOSYSTEM ANALYSIS
    • 5.3.1 SOFTWARE PROVIDERS
    • 5.3.2 PHARMACEUTICAL & BIOTECH COMPANIES
    • 5.3.3 CONTRACT RESEARCH ORGANIZATIONS (CROS)
    • 5.3.4 REGULATORY BODIES
    • 5.3.5 ACADEMIC & RESEARCH INSTITUTIONS
  • 5.4 CASE STUDY ANALYSIS
    • 5.4.1 CASE STUDY 1: OPTIMIZING ASCIMINIB DEVELOPMENT THROUGH ADVANCED PBPK MODELING
    • 5.4.2 CASE STUDY 2: COMPUTATIONAL DISCOVERY OF SELECTIVE WEE1 INHIBITORS FOR CANCER
    • 5.4.3 CASE STUDY 3: EFFICIENT CLINICAL TRIAL UTILIZING SCALE MANAGEMENT EXPERTISE
  • 5.5 VALUE CHAIN ANALYSIS
  • 5.6 PORTER'S FIVE FORCES ANALYSIS
    • 5.6.1 BARGAINING POWER OF SUPPLIERS
    • 5.6.2 BARGAINING POWER OF BUYERS
    • 5.6.3 THREAT OF SUBSTITUTES
    • 5.6.4 THREAT OF NEW ENTRANTS
    • 5.6.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.7 REGULATORY ANALYSIS
    • 5.7.1 REGULATORY LANDSCAPE
      • 5.7.1.1 North America
      • 5.7.1.2 Europe
      • 5.7.1.3 Asia Pacific
      • 5.7.1.4 Latin America
      • 5.7.1.5 Middle East & Africa
    • 5.7.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.8 PATENT ANALYSIS
    • 5.8.1 PATENT PUBLICATION TRENDS FOR BIOSIMULATION
    • 5.8.2 JURISDICTION AND TOP APPLICANT ANALYSIS
  • 5.9 TECHNOLOGY ANALYSIS
    • 5.9.1 KEY TECHNOLOGIES
      • 5.9.1.1 Mathematical modeling
      • 5.9.1.2 Software platforms
      • 5.9.1.3 Quantitative systems pharmacology (QSP)
    • 5.9.2 COMPLEMENTARY TECHNOLOGIES
      • 5.9.2.1 Data analytics
      • 5.9.2.2 Machine learning and AI
    • 5.9.3 ADJACENT TECHNOLOGIES
      • 5.9.3.1 In silico trials
  • 5.10 INDUSTRY TRENDS
    • 5.10.1 DISCOVERY OF BIOMARKERS
    • 5.10.2 ADOPTION IN PERSONALIZED MEDICINE
  • 5.11 PRICING ANALYSIS
    • 5.11.1 INDICATIVE PRICING ANALYSIS OF KEY PLAYERS, BY OFFERING, 2023
    • 5.11.2 AVERAGE SELLING PRICE TREND, BY REGION (QUALITATIVE)
  • 5.12 KEY CONFERENCES & EVENTS, 2024-2025
  • 5.13 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.13.1 BUYING CRITERIA
  • 5.14 TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.15 END-USER ANALYSIS
    • 5.15.1 UNMET NEEDS
    • 5.15.2 END-USER EXPECTATIONS
  • 5.16 INVESTMENT & FUNDING SCENARIO
  • 5.17 IMPACT OF AI/GEN AI ON BIOSIMULATION MARKET
    • 5.17.1 KEY USE CASES
    • 5.17.2 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
      • 5.17.2.1 Case study
      • 5.17.2.2 Bioinformatics market
      • 5.17.2.3 Drug discovery services market
      • 5.17.2.4 Drug discovery informatics market
    • 5.17.3 USER READINESS & IMPACT ASSESSMENT
      • 5.17.3.1 User readiness
        • 5.17.3.1.1 Pharmaceutical & biotechnology companies
        • 5.17.3.1.2 Contract research organizations
      • 5.17.3.2 Impact assessment
        • 5.17.3.2.1 User A: Pharmaceutical & biotechnology companies
          • 5.17.3.2.1.1 Implementation
          • 5.17.3.2.1.2 Impact
        • 5.17.3.2.2 User B: Academic & research institutes
          • 5.17.3.2.2.1 Implementation
          • 5.17.3.2.2.2 Impact

6 BIOSIMULATION MARKET, BY OFFERING

  • 6.1 INTRODUCTION
  • 6.2 SOFTWARE
    • 6.2.1 STANDALONE MODULES
      • 6.2.1.1 Molecular modeling & simulation software
        • 6.2.1.1.1 Growing importance of molecular modeling & simulation in drug discovery and development to accelerate market growth
      • 6.2.1.2 PK/PD modeling & simulation software
        • 6.2.1.2.1 Pivotal role in early drug development phase to boost market growth
      • 6.2.1.3 PBPK modeling & simulation software
        • 6.2.1.3.1 Widespread use by regulatory bodies to drive PBPK modeling & simulation software market
      • 6.2.1.4 Toxicity prediction software
        • 6.2.1.4.1 Pressing need for toxicity prediction in drug discovery and development is driving the market
      • 6.2.1.5 Clinical trial simulation software
        • 6.2.1.5.1 High failure rate of clinical trials to accelerate growth
      • 6.2.1.6 Other biosimulation software
    • 6.2.2 INTEGRATED SOFTWARE SUITES/PLATFORMS
      • 6.2.2.1 Need for efficient R&D tools to accelerate growth of integrated platforms
  • 6.3 SERVICES
    • 6.3.1 CONSULTING & ADVISORY
      • 6.3.1.1 Need to focus on core competencies to drive need for consulting & advisory services
    • 6.3.2 IMPLEMENTATION, TRAINING, AND SUPPORT
      • 6.3.2.1 Need for well-trained professionals and experts to accelerate market growth
    • 6.3.3 DATA ANALYSIS & INTERPRETATION
      • 6.3.3.1 Accurate and precise interpretation of data to drive need for data analysis & interpretation services

7 BIOSIMULATION MARKET, BY APPLICATION

  • 7.1 INTRODUCTION
  • 7.2 DRUG DISCOVERY
    • 7.2.1 TARGET IDENTIFICATION & VALIDATION
      • 7.2.1.1 Need for identification of optimal targets in drug discovery to drive market
    • 7.2.2 LEAD IDENTIFICATION & OPTIMIZATION
      • 7.2.2.1 Crucial role in facilitating viable drug discovery to accelerate market growth
  • 7.3 DRUG DEVELOPMENT
    • 7.3.1 PRECLINICAL TESTING
      • 7.3.1.1 PK/PD
        • 7.3.1.1.1 Critical role of PK/PD studies in drug development to drive market
      • 7.3.1.2 ADME/Toxicology
        • 7.3.1.2.1 Growing role in selection of potent drug molecules to boost market growth
    • 7.3.2 CLINICAL TRIALS
      • 7.3.2.1 Phase I
        • 7.3.2.1.1 Growing need to ease decision-making process to drive segmental growth
      • 7.3.2.2 Phase II
        • 7.3.2.2.1 Efficiency in dose assessment and product efficacy to drive growth
      • 7.3.2.3 Phase III
        • 7.3.2.3.1 Need to curtail large costs involved in trials to propel demand
      • 7.3.2.4 Phase IV/Post-marketing surveillance
        • 7.3.2.4.1 Ability to assist researchers in process innovation and decision support to drive adoption
  • 7.4 DISEASE MODELING
    • 7.4.1 CAPABILITY TO PREDICT DISEASE DYNAMICS AND INFORM THERAPEUTIC STRATEGIES TO DRIVE MARKET GROWTH
  • 7.5 MANUFACTURING & SUPPLY CHAIN MANAGEMENT
    • 7.5.1 PRODUCTION PLANNING & OPTIMIZATION
      • 7.5.1.1 Need for proper production planning and execution to drive market growth
    • 7.5.2 QUALITY CONTROL & PROCESS MONITORING
      • 7.5.2.1 Adherence to maintaining product quality to fuel market growth
    • 7.5.3 DEMAND FORECASTING & INVENTORY MANAGEMENT
      • 7.5.3.1 Need to forecast demand effectively to drive market growth
    • 7.5.4 RISK MANAGEMENT & CONTINGENCY PLANNING
      • 7.5.4.1 Need to maintain operational continuity to support market growth
    • 7.5.5 OTHER MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS
  • 7.6 OTHER APPLICATIONS

8 BIOSIMULATION MARKET, BY THERAPEUTIC AREA

  • 8.1 INTRODUCTION
  • 8.2 ONCOLOGY
    • 8.2.1 HIGH PREVALENCE OF CANCER AND SHORTAGE OF EFFECTIVE CANCER DRUGS TO DRIVE MARKET GROWTH
  • 8.3 CARDIOVASCULAR DISEASES
    • 8.3.1 RISING NEED FOR DRUGS TO TREAT CARDIOVASCULAR DISEASES TO BOOST MARKET
  • 8.4 NEUROLOGICAL DISORDERS
    • 8.4.1 NEED TO BOOST DRUG DISCOVERY AND DEVELOPMENT FOR NEUROLOGICAL DISORDERS TO SUPPORT MARKET GROWTH
  • 8.5 INFECTIOUS DISEASES
    • 8.5.1 RISING EPIDEMIC OUTBREAKS TO BOOST DRUG DISCOVERY ACTIVITY
  • 8.6 OTHER THERAPEUTIC AREAS

9 BIOSIMULATION MARKET, BY REVENUE MODEL

  • 9.1 INTRODUCTION
  • 9.2 LICENSE-BASED MODELS
    • 9.2.1 LICENSE-BASED MODELS TO ACCOUNT FOR LARGEST SHARE OF MARKET
  • 9.3 SUBSCRIPTION-BASED MODELS
    • 9.3.1 SUBSCRIPTION-BASED MODELS TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • 9.4 SERVICE-BASED MODELS
    • 9.4.1 SPECIALIZED SIMULATION EXPERTISE WITH SERVICE-BASED MODELS TO SUPPORT ADOPTION
  • 9.5 PAY-PER-USE MODELS
    • 9.5.1 RISING DEMAND FOR FLEXIBLE BIOSIMULATION SOLUTIONS WITHOUT UPFRONT COSTS TO SUPPORT MARKET GROWTH

10 BIOSIMULATION MARKET, BY DEPLOYMENT MODEL

  • 10.1 INTRODUCTION
  • 10.2 ON-PREMISE MODELS
    • 10.2.1 OPTIMAL CONTROL ON DEPLOYMENT AND DATA BACKUP TO SUPPORT MARKET UPTAKE
  • 10.3 CLOUD-BASED MODELS
    • 10.3.1 CLOUD-BASED MODEL TO EXPERIENCE HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • 10.4 HYBRID MODELS
    • 10.4.1 BALANCED CAPABILITIES OF HYBRID BIOSIMULATION MODELS TO ACCELERATE ADOPTION

11 BIOSIMULATION MARKET, BY END USER

  • 11.1 INTRODUCTION
  • 11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 11.2.1 INCREASING R&D EXPENDITURE FOR DRUG DISCOVERY AND DEVELOPMENT TO DRIVE MARKET
  • 11.3 CONTRACT RESEARCH ORGANIZATIONS
    • 11.3.1 RISING OUTSOURCING OF CLINICAL TRIAL ACTIVITIES TO CROS BY PHARMACEUTICAL COMPANIES TO DRIVE MARKET
  • 11.4 ACADEMIC & RESEARCH INSTITUTES
    • 11.4.1 FAVORABLE GOVERNMENT SUPPORT FOR RESEARCH TO SUPPORT MARKET GROWTH
  • 11.5 REGULATORY BODIES
    • 11.5.1 GROWING USAGE OF BIOSIMULATION SOFTWARE FOR CLINICAL TRIAL EFFICACY TO PROPEL MARKET GROWTH
  • 11.6 OTHER END USERS

12 BIOSIMULATION MARKET, BY REGION

  • 12.1 INTRODUCTION
  • 12.2 NORTH AMERICA
    • 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 12.2.2 US
      • 12.2.2.1 Rising government funding for pharmaceutical R&D to drive market
    • 12.2.3 CANADA
      • 12.2.3.1 Increasing funding by Canadian government in healthcare to drive market
  • 12.3 EUROPE
    • 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 12.3.2 GERMANY
      • 12.3.2.1 High number of sponsored clinical trials to drive uptake of biosimulation
    • 12.3.3 UK
      • 12.3.3.1 Investments by pharmaceutical sponsors for drug discovery services to boost market
    • 12.3.4 FRANCE
      • 12.3.4.1 Growing R&D pipeline for clinical trials to drive market
    • 12.3.5 ITALY
      • 12.3.5.1 Increasing government funds and favorable regulatory scenarios to fuel uptake
    • 12.3.6 SPAIN
      • 12.3.6.1 Established network of research centers to propel market
    • 12.3.7 REST OF EUROPE
  • 12.4 ASIA PACIFIC
    • 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 12.4.2 CHINA
      • 12.4.2.1 Low cost of drug development and large pharmaceutical R&D base to drive market
    • 12.4.3 INDIA
      • 12.4.3.1 Growing pharmaceutical industry to fuel uptake of biosimulation
    • 12.4.4 JAPAN
      • 12.4.4.1 Established drug development infrastructure and biomedical research capabilities to support market growth
    • 12.4.5 REST OF ASIA PACIFIC
  • 12.5 LATIN AMERICA
    • 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 12.5.2 BRAZIL
      • 12.5.2.1 Advancing biosimulation in region to support market growth
    • 12.5.3 MEXICO
      • 12.5.3.1 Government initiatives to enhance digital health to propel market growth
    • 12.5.4 REST OF LATIN AMERICA
  • 12.6 MIDDLE EAST & AFRICA
    • 12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
    • 12.6.2 GCC COUNTRIES
      • 12.6.2.1 Increase in healthcare investments to support market growth
    • 12.6.3 REST OF MIDDLE EAST & AFRICA

13 COMPETITIVE LANDSCAPE

  • 13.1 INTRODUCTION
  • 13.2 KEY PLAYER STRATEGY/RIGHT TO WIN
    • 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN BIOSIMULATION MARKET
  • 13.3 REVENUE ANALYSIS, 2019-2023
  • 13.4 MARKET SHARE ANALYSIS, 2023
    • 13.4.1 CERTARA, USA (US)
    • 13.4.2 DASSAULT SYSTEMES (FRANCE)
    • 13.4.3 SCHRODINGER, INC. (US)
    • 13.4.4 SIMULATIONS PLUS (US)
    • 13.4.5 ADVANCED CHEMISTRY DEVELOPMENT, INC. (CANADA)
  • 13.5 RANKING OF KEY MARKET PLAYERS
  • 13.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 13.6.1 STARS
    • 13.6.2 EMERGING LEADERS
    • 13.6.3 PERVASIVE PLAYERS
    • 13.6.4 PARTICIPANTS
    • 13.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
      • 13.6.5.1 Company footprint
      • 13.6.5.2 Offering footprint
      • 13.6.5.3 Application footprint
      • 13.6.5.4 End-user footprint
      • 13.6.5.5 Region footprint
  • 13.7 COMPANY EVALUATION MATRIX: START-UP/SMES, 2023
    • 13.7.1 PROGRESSIVE COMPANIES
    • 13.7.2 RESPONSIVE COMPANIES
    • 13.7.3 DYNAMIC COMPANIES
    • 13.7.4 STARTING BLOCKS
    • 13.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 13.8 COMPANY EVALUATION & FINANCIAL METRICS
  • 13.9 BRAND/PRODUCT COMPARISON
  • 13.10 COMPETITIVE SCENARIO
    • 13.10.1 PRODUCT LAUNCHES & ENHANCEMENTS
    • 13.10.2 DEALS
    • 13.10.3 EXPANSIONS
    • 13.10.4 OTHER DEVELOPMENTS

14 COMPANY PROFILES

  • 14.1 KEY PLAYERS
    • 14.1.1 CERTARA, USA
      • 14.1.1.1 Business overview
      • 14.1.1.2 Products & services offered
      • 14.1.1.3 Recent developments
        • 14.1.1.3.1 Product launches & enhancements
        • 14.1.1.3.2 Deals
      • 14.1.1.4 MnM view
        • 14.1.1.4.1 Right to win
        • 14.1.1.4.2 Strategic choices
        • 14.1.1.4.3 Weaknesses & competitive threats
    • 14.1.2 DASSAULT SYSTEMES
      • 14.1.2.1 Business overview
      • 14.1.2.2 Products & services offered
      • 14.1.2.3 Recent developments
        • 14.1.2.3.1 Deals
      • 14.1.2.4 MnM view
        • 14.1.2.4.1 Right to win
        • 14.1.2.4.2 Strategic choices
        • 14.1.2.4.3 Weaknesses & competitive threats
    • 14.1.3 SCHRODINGER, INC.
      • 14.1.3.1 Business overview
      • 14.1.3.2 Products & services offered
      • 14.1.3.3 Recent developments
        • 14.1.3.3.1 Deals
      • 14.1.3.4 MnM view
        • 14.1.3.4.1 Right to win
        • 14.1.3.4.2 Strategic choices
        • 14.1.3.4.3 Weaknesses & competitive threats
    • 14.1.4 SIMULATIONS PLUS
      • 14.1.4.1 Business overview
      • 14.1.4.2 Products & services offered
      • 14.1.4.3 Recent developments
        • 14.1.4.3.1 Product launches & enhancements
        • 14.1.4.3.2 Deals
        • 14.1.4.3.3 Other developments
    • 14.1.5 ADVANCED CHEMISTRY DEVELOPMENT, INC.
      • 14.1.5.1 Business overview
      • 14.1.5.2 Products & services offered
      • 14.1.5.3 Recent developments
        • 14.1.5.3.1 Product launches & enhancements
        • 14.1.5.3.2 Deals
    • 14.1.6 CHEMICAL COMPUTING GROUP ULC
      • 14.1.6.1 Business overview
      • 14.1.6.2 Products & services offered
      • 14.1.6.3 Recent developments
        • 14.1.6.3.1 Deals
    • 14.1.7 ROSA & CO. LLC
      • 14.1.7.1 Business overview
      • 14.1.7.2 Products & services offered
    • 14.1.8 GENEDATA AG (A DANAHER COMPANY)
      • 14.1.8.1 Business overview
      • 14.1.8.2 Products & services offered
      • 14.1.8.3 Recent developments
        • 14.1.8.3.1 Product launches & enhancements
        • 14.1.8.3.2 Deals
    • 14.1.9 PHYSIOMICS PLC
      • 14.1.9.1 Business overview
      • 14.1.9.2 Products & services offered
      • 14.1.9.3 Recent developments
        • 14.1.9.3.1 Deals
    • 14.1.10 IN SILICO BIOSCIENCES
      • 14.1.10.1 Business overview
      • 14.1.10.2 Products & services offered
    • 14.1.11 ALLUCENT
      • 14.1.11.1 Business overview
      • 14.1.11.2 Products & services offered
      • 14.1.11.3 Recent developments
        • 14.1.11.3.1 Deals
        • 14.1.11.3.2 Expansions
    • 14.1.12 OPENEYE, CADENCE MOLECULAR SCIENCES
      • 14.1.12.1 Business overview
      • 14.1.12.2 Products & services offered
      • 14.1.12.3 Recent developments
        • 14.1.12.3.1 Product enhancements
        • 14.1.12.3.2 Deals
        • 14.1.12.3.3 Expansions
    • 14.1.13 CELLWORKS GROUP, INC.
      • 14.1.13.1 Business overview
      • 14.1.13.2 Products & services offered
      • 14.1.13.3 Recent developments
        • 14.1.13.3.1 Expansions
    • 14.1.14 VERISIM LIFE
      • 14.1.14.1 Business overview
      • 14.1.14.2 Products & services offered
      • 14.1.14.3 Recent developments
        • 14.1.14.3.1 Deals
        • 14.1.14.3.2 Other developments
    • 14.1.15 NETABOLICS
      • 14.1.15.1 Business overview
      • 14.1.15.2 Products & services offered
    • 14.1.16 CHARNWOOD DISCOVERY
      • 14.1.16.1 Business overview
      • 14.1.16.2 Products & services offered
      • 14.1.16.3 Recent developments
        • 14.1.16.3.1 Deals
    • 14.1.17 THE MATHWORKS, INC.
      • 14.1.17.1 Business overview
      • 14.1.17.2 Products & services offered
      • 14.1.17.3 Recent developments
        • 14.1.17.3.1 Product enhancements
    • 14.1.18 ANSYS, INC.
      • 14.1.18.1 Business overview
      • 14.1.18.2 Products & services offered
  • 14.2 START-UP/SME PLAYERS
    • 14.2.1 INSTEM GROUP OF COMPANIES
    • 14.2.2 INSILICO MEDICINE
    • 14.2.3 SCM - SOFTWARE CHEMISTRY & MATERIALS
    • 14.2.4 BIOSYMETRICS, INC.
    • 14.2.5 ATOMWISE INC.
    • 14.2.6 INSITRO
    • 14.2.7 CLINITHINK

15 APPENDIX

  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 15.3 CUSTOMIZATION OPTIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 BIOSIMULATION MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 2 BIOSIMULATION MARKET: PORTER'S FIVE FORCES
  • TABLE 3 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 4 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 5 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 6 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 7 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 8 INDICATIVE PRICING ANALYSIS OF KEY PLAYERS, BY OFFERING
  • TABLE 9 BIOSIMULATION MARKET: KEY CONFERENCES AND EVENTS, 2024-2025
  • TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP 3 END USERS (%)
  • TABLE 11 KEY BUYING CRITERIA FOR TOP 3 END USERS
  • TABLE 12 UNMET NEEDS IN BIOSIMULATION MARKET
  • TABLE 13 END-USER EXPECTATIONS IN BIOSIMULATION MARKET
  • TABLE 14 BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 15 BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 16 BIOSIMULATION SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 17 BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 18 BIOSIMULATION MARKET FOR STANDALONE MODULES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 19 BIOSIMULATION MARKET FOR MOLECULAR MODELING & SIMULATION SOFTWARE, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 20 BIOSIMULATION MARKET FOR PK/PD MODELING & SIMULATION SOFTWARE, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 21 BIOSIMULATION MARKET FOR PBPK MODELING & SIMULATION SOFTWARE, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 22 BIOSIMULATION MARKET FOR TOXICITY PREDICTION SOFTWARE, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 23 BIOSIMULATION MARKET FOR CLINICAL TRIAL SIMULATION SOFTWARE, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 24 BIOSIMULATION MARKET FOR OTHER BIOSIMULATION SOFTWARE, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 25 BIOSIMULATION MARKET FOR INTEGRATED SOFTWARE SUITES/PLATFORMS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 26 BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 27 BIOSIMULATION SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 28 BIOSIMULATION MARKET FOR CONSULTING & ADVISORY SERVICES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 29 BIOSIMULATION MARKET FOR IMPLEMENTATION, TRAINING, AND SUPPORT SERVICES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 30 BIOSIMULATION MARKET FOR DATA ANALYSIS & INTERPRETATION SERVICES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 31 BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 32 BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 33 BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 34 BIOSIMULATION MARKET FOR TARGET IDENTIFICATION & VALIDATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 35 BIOSIMULATION MARKET FOR LEAD IDENTIFICATION & OPTIMIZATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 36 BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 37 BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 38 BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 39 BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 40 BIOSIMULATION MARKET FOR PK/PD, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 41 BIOSIMULATION MARKET FOR ADME/TOXICOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 42 BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 43 BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 44 BIOSIMULATION MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 45 BIOSIMULATION MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 46 BIOSIMULATION MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 47 BIOSIMULATION MARKET FOR PHASE IV/POST-MARKETING SURVEILLANCE, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 48 BIOSIMULATION MARKET FOR DISEASE MODELING APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 49 BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 50 BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 51 BIOSIMULATION MARKET FOR PRODUCTION PLANNING & OPTIMIZATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 52 BIOSIMULATION MARKET FOR QUALITY CONTROL & PROCESS MONITORING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 53 BIOSIMULATION MARKET FOR DEMAND FORECASTING & INVENTORY MANAGEMENT, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 54 BIOSIMULATION MARKET FOR RISK MANAGEMENT & CONTINGENCY PLANNING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 55 BIOSIMULATION MARKET FOR OTHER MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 56 BIOSIMULATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 57 BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 58 BIOSIMULATION MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 59 BIOSIMULATION MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 60 BIOSIMULATION MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 61 BIOSIMULATION MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 62 BIOSIMULATION MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 63 BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
  • TABLE 64 BIOSIMULATION MARKET FOR LICENSE-BASED MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 65 BIOSIMULATION MARKET FOR SUBSCRIPTION-BASED MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 66 BIOSIMULATION MARKET FOR SERVICE-BASED MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 67 BIOSIMULATION MARKET FOR PAY-PER-USE MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 68 BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
  • TABLE 69 BIOSIMULATION MARKET FOR ON-PREMISE MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 70 BIOSIMULATION MARKET FOR CLOUD-BASED MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 71 BIOSIMULATION MARKET FOR HYBRID MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 72 BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 73 BIOSIMULATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 74 BIOSIMULATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 75 BIOSIMULATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 76 BIOSIMULATION MARKET FOR REGULATORY BODIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 77 BIOSIMULATION MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 78 BIOSIMULATION MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 79 NORTH AMERICA: BIOSIMULATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 80 NORTH AMERICA: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 81 NORTH AMERICA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 82 NORTH AMERICA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 83 NORTH AMERICA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 84 NORTH AMERICA: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 85 NORTH AMERICA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 86 NORTH AMERICA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 87 NORTH AMERICA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 88 NORTH AMERICA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 89 NORTH AMERICA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 90 NORTH AMERICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 91 NORTH AMERICA: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
  • TABLE 92 NORTH AMERICA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
  • TABLE 93 NORTH AMERICA: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 94 US: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 95 US: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 96 US: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 97 US: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 98 US: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 99 US: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 100 US: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 101 US: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 102 US: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 103 US: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 104 US: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 105 US: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
  • TABLE 106 US: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
  • TABLE 107 US: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 108 CANADA: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 109 CANADA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 110 CANADA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 111 CANADA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 112 CANADA: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 113 CANADA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 114 CANADA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 115 CANADA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 116 CANADA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 117 CANADA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 118 CANADA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 119 CANADA: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
  • TABLE 120 CANADA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
  • TABLE 121 CANADA: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 122 EUROPE: BIOSIMULATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 123 EUROPE: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 124 EUROPE: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 125 EUROPE: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 126 EUROPE: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 127 EUROPE: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 128 EUROPE: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 129 EUROPE: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 130 EUROPE: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 131 EUROPE: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 132 EUROPE: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 133 EUROPE: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 134 EUROPE: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
  • TABLE 135 EUROPE: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
  • TABLE 136 EUROPE: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 137 GERMANY: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 138 GERMANY: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 139 GERMANY: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 140 GERMANY: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 141 GERMANY: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 142 GERMANY: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 143 GERMANY: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 144 GERMANY: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 145 GERMANY: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 146 GERMANY: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 147 GERMANY: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 148 GERMANY: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
  • TABLE 149 GERMANY: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
  • TABLE 150 GERMANY: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 151 UK: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 152 UK: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 153 UK: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 154 UK: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 155 UK: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 156 UK: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 157 UK: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 158 UK: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 159 UK: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 160 UK: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 161 UK: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 162 UK: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
  • TABLE 163 UK: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
  • TABLE 164 UK: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 165 FRANCE: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 166 FRANCE: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 167 FRANCE: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 168 FRANCE: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 169 FRANCE: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 170 FRANCE: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 171 FRANCE: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 172 FRANCE: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 173 FRANCE: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 174 FRANCE: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 175 FRANCE: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 176 FRANCE: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
  • TABLE 177 FRANCE: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
  • TABLE 178 FRANCE: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 179 ITALY: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 180 ITALY: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 181 ITALY: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 182 ITALY: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 183 ITALY: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 184 ITALY: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 185 ITALY: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 186 ITALY: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 187 ITALY: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 188 ITALY: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 189 ITALY: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 190 ITALY: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
  • TABLE 191 ITALY: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
  • TABLE 192 ITALY: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 193 SPAIN: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 194 SPAIN: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 195 SPAIN: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 196 SPAIN: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 197 SPAIN: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 198 SPAIN: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 199 SPAIN: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 200 SPAIN: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 201 SPAIN: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 202 SPAIN: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 203 SPAIN: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 204 SPAIN: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
  • TABLE 205 SPAIN: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
  • TABLE 206 SPAIN: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 207 REST OF EUROPE: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 208 REST OF EUROPE: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 209 REST OF EUROPE: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 210 REST OF EUROPE: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 211 REST OF EUROPE: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 212 REST OF EUROPE: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 213 REST OF EUROPE: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 214 REST OF EUROPE: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 215 REST OF EUROPE: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 216 REST OF EUROPE: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 217 REST OF EUROPE: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 218 REST OF EUROPE: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
  • TABLE 219 REST OF EUROPE: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
  • TABLE 220 REST OF EUROPE: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 221 ASIA PACIFIC: BIOSIMULATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 222 ASIA PACIFIC: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 223 ASIA PACIFIC: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 224 ASIA PACIFIC: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 225 ASIA PACIFIC: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 226 ASIA PACIFIC: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 227 ASIA PACIFIC: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 228 ASIA PACIFIC: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 229 ASIA PACIFIC: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 230 ASIA PACIFIC: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 231 ASIA PACIFIC: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 232 ASIA PACIFIC: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 233 ASIA PACIFIC: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
  • TABLE 234 ASIA PACIFIC: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
  • TABLE 235 ASIA PACIFIC: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 236 CHINA: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 237 CHINA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 238 CHINA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 239 CHINA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 240 CHINA: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 241 CHINA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 242 CHINA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 243 CHINA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 244 CHINA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 245 CHINA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 246 CHINA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 247 CHINA: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
  • TABLE 248 CHINA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
  • TABLE 249 CHINA: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 250 INDIA: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 251 INDIA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 252 INDIA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 253 INDIA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 254 INDIA: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 255 INDIA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 256 INDIA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 257 INDIA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 258 INDIA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 259 INDIA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 260 INDIA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 261 INDIA: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
  • TABLE 262 INDIA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
  • TABLE 263 INDIA: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 264 JAPAN: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 265 JAPAN: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 266 JAPAN: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 267 JAPAN: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 268 JAPAN: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 269 JAPAN: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 270 JAPAN: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 271 JAPAN: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 272 JAPAN: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 273 JAPAN: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 274 JAPAN: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 275 JAPAN: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
  • TABLE 276 JAPAN: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
  • TABLE 277 JAPAN: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 278 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 279 REST OF ASIA PACIFIC: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 280 REST OF ASIA PACIFIC: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 281 REST OF ASIA PACIFIC: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 282 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 283 REST OF ASIA PACIFIC: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 284 REST OF ASIA PACIFIC: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 285 REST OF ASIA PACIFIC: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 286 REST OF ASIA PACIFIC: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 287 REST OF ASIA PACIFIC: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 288 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 289 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
  • TABLE 290 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
  • TABLE 291 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 292 LATIN AMERICA: BIOSIMULATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 293 LATIN AMERICA: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 294 LATIN AMERICA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 295 LATIN AMERICA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 296 LATIN AMERICA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 297 LATIN AMERICA: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 298 LATIN AMERICA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 299 LATIN AMERICA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 300 LATIN AMERICA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 301 LATIN AMERICA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 302 LATIN AMERICA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 303 LATIN AMERICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 304 LATIN AMERICA: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
  • TABLE 305 LATIN AMERICA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
  • TABLE 306 LATIN AMERICA: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 307 BRAZIL: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 308 BRAZIL: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 309 BRAZIL: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 310 BRAZIL: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 311 BRAZIL: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 312 BRAZIL: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 313 BRAZIL: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 314 BRAZIL: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 315 BRAZIL: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 316 BRAZIL: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 317 BRAZIL: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 318 BRAZIL: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
  • TABLE 319 BRAZIL: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
  • TABLE 320 BRAZIL: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 321 MEXICO: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 322 MEXICO: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 323 MEXICO: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 324 MEXICO: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 325 MEXICO: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 326 MEXICO: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 327 MEXICO: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 328 MEXICO: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 329 MEXICO: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 330 MEXICO: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 331 MEXICO: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 332 MEXICO: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
  • TABLE 333 MEXICO: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
  • TABLE 334 MEXICO: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 335 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 336 REST OF LATIN AMERICA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 337 REST OF LATIN AMERICA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 338 REST OF LATIN AMERICA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 339 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 340 REST OF LATIN AMERICA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 341 REST OF LATIN AMERICA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 342 REST OF LATIN AMERICA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 343 REST OF LATIN AMERICA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 344 REST OF LATIN AMERICA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 345 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 346 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
  • TABLE 347 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
  • TABLE 348 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 349 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 350 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 351 MIDDLE EAST & AFRICA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 352 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 353 MIDDLE EAST & AFRICA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 354 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 355 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 356 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 357 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 358 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 359 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 360 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 361 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
  • TABLE 362 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
  • TABLE 363 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 364 GCC COUNTRIES: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 365 GCC COUNTRIES: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 366 GCC COUNTRIES: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 367 GCC COUNTRIES: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 368 GCC COUNTRIES: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 369 GCC COUNTRIES: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 370 GCC COUNTRIES: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 371 GCC COUNTRIES: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 372 GCC COUNTRIES: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 373 GCC COUNTRIES: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 374 GCC COUNTRIES: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 375 GCC COUNTRIES: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
  • TABLE 376 GCC COUNTRIES: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
  • TABLE 377 GCC COUNTRIES: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 378 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 379 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 380 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 381 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 382 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 383 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 384 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 385 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 386 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 387 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 388 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 389 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
  • TABLE 390 REST OF MIDDLE EAST & AFRICA NORTH AMERICA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
  • TABLE 391 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 392 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOSIMULATION MARKET
  • TABLE 393 BIOSIMULATION MARKET: DEGREE OF COMPETITION
  • TABLE 394 BIOSIMULATION MARKET: OFFERING FOOTPRINT
  • TABLE 395 BIOSIMULATION MARKET: APPLICATION FOOTPRINT
  • TABLE 396 BIOSIMULATION MARKET: END-USER FOOTPRINT
  • TABLE 397 BIOSIMULATION MARKET: REGION FOOTPRINT
  • TABLE 398 BIOSIMULATION MARKET: DETAILED LIST OF KEY START-UPS/SMES
  • TABLE 399 BIOSIMULATION MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
  • TABLE 400 BIOSIMULATION MARKET: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021-OCTOBER 2024
  • TABLE 401 BIOSIMULATION MARKET: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 402 BIOSIMULATION MARKET: EXPANSIONS, JANUARY 2021-OCTOBER 2024
  • TABLE 403 BIOSIMULATION MARKET: OTHER DEVELOPMENTS, JANUARY 2021-OCTOBER 2024
  • TABLE 404 CERTARA, USA: COMPANY OVERVIEW
  • TABLE 405 CERTARA, USA: PRODUCTS & SERVICES OFFERED
  • TABLE 406 CERTARA, USA: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021-OCTOBER 2024
  • TABLE 407 CERTARA, USA: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 408 DASSAULT SYSTEMES: COMPANY OVERVIEW
  • TABLE 409 DASSAULT SYSTEMES: PRODUCTS & SERVICES OFFERED
  • TABLE 410 DASSAULT SYSTEMES: DEALS, JANUARY 2021-JUNE 2024
  • TABLE 411 SCHRODINGER, INC.: COMPANY OVERVIEW
  • TABLE 412 SCHRODINGER, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 413 SCHRODINGER, INC.: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 414 SIMULATIONS PLUS: COMPANY OVERVIEW
  • TABLE 415 SIMULATIONS PLUS: PRODUCTS & SERVICES OFFERED
  • TABLE 416 SIMULATIONS PLUS: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021-OCTOBER 2024
  • TABLE 417 SIMULATIONS PLUS: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 418 SIMULATIONS PLUS: OTHER DEVELOPMENTS, JANUARY 2021-OCTOBER 2024
  • TABLE 419 ADVANCED CHEMISTRY DEVELOPMENT, INC.: COMPANY OVERVIEW
  • TABLE 420 ADVANCED CHEMISTRY DEVELOPMENT, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 421 ADVANCED CHEMISTRY DEVELOPMENT, INC.: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021-OCTOBER 2024
  • TABLE 422 ADVANCED CHEMISTRY DEVELOPMENT, INC.: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 423 CHEMICAL COMPUTING GROUP ULC: COMPANY OVERVIEW
  • TABLE 424 CHEMICAL COMPUTING GROUP ULC: PRODUCTS & SERVICES OFFERED
  • TABLE 425 CHEMICAL COMPUTING GROUP ULC: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 426 ROSA & CO. LLC: COMPANY OVERVIEW
  • TABLE 427 ROSA & CO. LLC: PRODUCTS & SERVICES OFFERED
  • TABLE 428 GENEDATA AG (A DANAHER COMPANY): COMPANY OVERVIEW
  • TABLE 429 GENEDATA AG (A DANAHER COMPANY): PRODUCTS & SERVICES OFFERED
  • TABLE 430 GENEDATA AG (A DANAHER COMPANY): PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021-OCTOBER 2024
  • TABLE 431 GENEDATA AG (A DANAHER COMPANY): DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 432 PHYSIOMICS PLC: COMPANY OVERVIEW
  • TABLE 433 PHYSIOMICS PLC: PRODUCTS & SERVICES OFFERED
  • TABLE 434 PHYSIOMICS PLC: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 435 IN SILICO BIOSCIENCES: COMPANY OVERVIEW
  • TABLE 436 IN SILICO BIOSCIENCES: PRODUCTS & SERVICES OFFERED
  • TABLE 437 ALLUCENT: COMPANY OVERVIEW
  • TABLE 438 ALLUCENT: PRODUCTS & SERVICES OFFERED
  • TABLE 439 ALLUCENT: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 440 ALLUCENT: EXPANSIONS, JANUARY 2021-OCTOBER 2024
  • TABLE 441 OPENEYE, CADENCE MOLECULAR SCIENCES: COMPANY OVERVIEW
  • TABLE 442 OPENEYE, CADENCE MOLECULAR SCIENCES: PRODUCTS & SERVICES OFFERED
  • TABLE 443 OPENEYE, CADENCE MOLECULAR SCIENCES: PRODUCT ENHANCEMENTS, JANUARY 2021-OCTOBER 2024
  • TABLE 444 OPENEYE, CADENCE MOLECULAR SCIENCES: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 445 OPENEYE, CADENCE MOLECULAR SCIENCES: EXPANSIONS, JANUARY 2021-OCTOBER 2024
  • TABLE 446 CELLWORKS GROUP, INC.: COMPANY OVERVIEW
  • TABLE 447 CELLWORKS GROUP, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 448 CELLWORKS GROUP, INC.: EXPANSIONS, JANUARY 2021-OCTOBER 2024
  • TABLE 449 VERISIM LIFE: COMPANY OVERVIEW
  • TABLE 450 VERISIM LIFE: PRODUCTS & SERVICES OFFERED
  • TABLE 451 VERISIM LIFE: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 452 VERISIM LIFE: OTHER DEVELOPMENTS, JANUARY 2021-OCTOBER 2024
  • TABLE 453 NETABOLICS: COMPANY OVERVIEW
  • TABLE 454 NETABOLICS: PRODUCTS & SERVICES OFFERED
  • TABLE 455 CHARNWOOD DISCOVERY: COMPANY OVERVIEW
  • TABLE 456 CHARNWOOD DISCOVERY: PRODUCTS & SERVICES OFFERED
  • TABLE 457 CHARNWOOD DISCOVERY: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 458 THE MATHWORKS, INC.: COMPANY OVERVIEW
  • TABLE 459 THE MATHWORKS, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 460 THE MATHWORKS, INC.: PRODUCT ENHANCEMENTS, JANUARY 2021-OCTOBER 2024
  • TABLE 461 ANSYS, INC.: COMPANY OVERVIEW
  • TABLE 462 ANSYS, INC.: PRODUCTS & SERVICES OFFERED

List of Figures

  • FIGURE 1 BIOSIMULATION MARKET SEGMENTATION & REGIONAL SCOPE
  • FIGURE 2 RESEARCH DESIGN
  • FIGURE 3 PRIMARY SOURCES
  • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
  • FIGURE 6 TOP-DOWN APPROACH
  • FIGURE 7 CAGR PROJECTIONS, 2024-2029
  • FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 9 DATA TRIANGULATION
  • FIGURE 10 BIOSIMULATION MARKET, BY OFFERING, 2024 VS. 2029 (USD MILLION)
  • FIGURE 11 BIOSIMULATION MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
  • FIGURE 12 BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2024 VS. 2029 (USD MILLION)
  • FIGURE 13 BIOSIMULATION MARKET, BY REVENUE MODEL, 2024 VS. 2029 (USD MILLION)
  • FIGURE 14 BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2024 VS. 2029 (USD MILLION)
  • FIGURE 15 BIOSIMULATION MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 16 GEOGRAPHIC SNAPSHOT OF BIOSIMULATION MARKET
  • FIGURE 17 INCREASING R&D EXPENDITURE ON DRUG DISCOVERY & DEVELOPMENT BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DRIVE MARKET
  • FIGURE 18 CHINA DOMINATED MARKET IN ASIA PACIFIC IN 2023
  • FIGURE 19 INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • FIGURE 20 NORTH AMERICA TO DOMINATE BIOSIMULATION MARKET DURING FORECAST PERIOD
  • FIGURE 21 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD
  • FIGURE 22 BIOSIMULATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 23 BIOSIMULATION MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 24 BIOSIMULATION MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 25 BIOSIMULATION MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 26 PATENT PUBLICATION TRENDS IN BIOSIMULATION MARKET, 2015-2024
  • FIGURE 27 BIOSIMULATION MARKET: PATENT ANALYSIS, JANUARY 2015-SEPTEMBER 2024
  • FIGURE 28 INDICATIVE PRICING ANALYSIS FOR BIOSIMULATION SOFTWARE
  • FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP 3 END USERS
  • FIGURE 30 KEY BUYING CRITERIA FOR TOP 3 END USERS
  • FIGURE 31 TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • FIGURE 32 BIOSIMULATION MARKET: INVESTMENT & FUNDING SCENARIO
  • FIGURE 33 MARKET POTENTIAL OF AI/GENERATIVE AI ON BIOSIMULATION
  • FIGURE 34 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
  • FIGURE 35 NORTH AMERICA: BIOSIMULATION MARKET SNAPSHOT
  • FIGURE 36 ASIA PACIFIC: BIOSIMULATION MARKET SNAPSHOT
  • FIGURE 37 REVENUE ANALYSIS OF KEY PLAYERS IN BIOSIMULATION MARKET, 2019-2023 (USD BILLION)
  • FIGURE 38 BIOSIMULATION MARKET: MARKET SHARE ANALYSIS (2023)
  • FIGURE 39 RANKING OF KEY PLAYERS IN BIOSIMULATION MARKET, 2023
  • FIGURE 40 BIOSIMULATION MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 41 BIOSIMULATION MARKET: COMPANY FOOTPRINT
  • FIGURE 42 BIOSIMULATION MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2023
  • FIGURE 43 EV/EBITDA OF KEY VENDORS
  • FIGURE 44 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF BIOSIMULATION VENDORS
  • FIGURE 45 BIOSIMULATION MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 46 CERTARA, USA: COMPANY SNAPSHOT (2023)
  • FIGURE 47 DASSAULT SYSTEMES: COMPANY SNAPSHOT (2023)
  • FIGURE 48 SCHRODINGER, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 49 SIMULATIONS PLUS: COMPANY SNAPSHOT (2023)
  • FIGURE 50 GENEDATA AG (A DANAHER COMPANY): COMPANY SNAPSHOT (2023)
  • FIGURE 51 PHYSIOMICS PLC: COMPANY SNAPSHOT (2023)
  • FIGURE 52 OPENEYE, CADENCE MOLECULAR SCIENCES: COMPANY SNAPSHOT (2023)
  • FIGURE 53 ANSYS, INC.: COMPANY SNAPSHOT (2023)